4,5,6,7-Tetrabromobenzimidazole CAS: 577779-57-8
MF: C7H2Br4N2
MW: 433.72
An inhibitor of protein kinase CK2.

4,5,6,7-Tetrabromobenzimidazole (CAS 577779-57-8)

4,5,6,7-Tetrabromobenzimidazole | CAS 577779-57-8 is rated 5.0 out of 5 by 1.
  • y_2021, m_9, d_17, h_20
  • bvseo_bulk, prod_bvrr, vn_bulk_3.0.19
  • cp_1, bvpage1
  • co_hasreviews, tv_0, tr_1
  • loc_en_US, sid_217031, prod, sort_[SortEntry(order=SUBMISSION_TIME, direction=DESCENDING)]
  • clientName_scbt
  • bvseo_sdk, java_sdk, bvseo-3.2.0
  • CLOUD, getAggregateRating, 112ms
  • REVIEWS, PRODUCT
loading
5
1
4
0
3
0
2
0
1
0
Application: 4,5,6,7-Tetrabromobenzimidazole is an inhibitor of Casein Kinase II (protein kinase CK2)
CAS Number: 577779-57-8
Purity: 98%
Molecular Weight: 433.72
Molecular Formula: C7H2Br4N2
Supplemental Information: This is classified as a Dangerous Good for transport and may be subject to additional shipping charges.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data (including water content).
loading

4,5,6,7-Tetrabromobenzimidazole is a selective ATP-competitive inhibitor of protein kinase CK2 from such divergent sources as yeast, rat liver, Neurospora erassa and Candida tropicalis, with Ki values in the range of 0.5-1uM. It is virtually inactive against PKA, PKC, and a very weak inhibitor of protein kinase CK1.


References

Zien, P., et al.: Biochemical and Biophysical Res. Commun., 306, 129 (2003)

Physical State :
Solid
Solubility :
Soluble in DMSO, Ethanol and Methanol
Storage :
Store at -20° C
Melting Point :
330-332°C (lit.)
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
PubChem CID :
MDL Number :
MFCD04116202
SMILES :
C1=NC2=C(N1)C(=C(C(=C2Br)Br)Br)Br

Download SDS (MSDS)

Certificate of Analysis

Adobe Acrobat Reader is required to reliably view,
print and comment on PDF documents

  • bvseo_sdk, java_sdk, bvseo-3.2.0
  • CLOUD, getContent, 109ms
  • QUESTIONS, PRODUCT
  • bvseo-msg: The resource to the URL or file is currently unavailable.;
Rated 5 out of 5 by from Luo Luo, W. et al. (PubMed 23358686) used the CK2 inhibitor 4,5,6,7-Tetrabromobenzimidazole to demonstrate that inhibition of protein kinase CK2 reduces Cyp24a1 expression and enhances 1,25-dihydroxyvitamin D(3) antitumor activity in human prostate cancer cells. -SCBT Publication Review
Date published: 2015-03-15
  • y_2021, m_9, d_17, h_20
  • bvseo_bulk, prod_bvrr, vn_bulk_3.0.19
  • cp_1, bvpage1
  • co_hasreviews, tv_0, tr_1
  • loc_en_US, sid_217031, prod, sort_[SortEntry(order=SUBMISSION_TIME, direction=DESCENDING)]
  • clientName_scbt
  • bvseo_sdk, java_sdk, bvseo-3.2.0
  • CLOUD, getReviews, 14ms
  • REVIEWS, PRODUCT